NUMIFNuminus Wellness Inc.
The Read
5% surge after securing better-than-feared financing in July 2026, but faced a 45.
The schedule
- Thu15Oct
Through late 2026, evolving Canadian and U.S. regulatory and reimbursement signals for psychedelic-assisted mental health treatments may influence Numinus’s growth prospects from around $0.02.
- Sun29Nov
- Mon1Feb
If financial pressure persists into early 2027, Numinus may announce strategic alternatives, ranging from clinic sales to a full-company transaction, from a base near $0.02.
- Sun28Feb
- Sun30May
- Sun29Aug
Past
- Mon31Aug
FQ3 2026 results on 2026-08-31 at a $0.02 reference price, with emphasis on clinic utilization, psychedelic-assisted therapy adoption, and any post-financing operating plan.
- Wed15Jul
Actual outcome: Bull · $0.04 at outcome
Numinus successfully navigated its balance sheet recapitalization, securing necessary financing on better-than-feared terms. By avoiding a highly dilutive equity raise at the $0.02 level, the company alleviated immediate liquidity and negative equity concerns. This stabilization of the balance sheet restored investor confidence, driving the stock higher toward the bull target.
By mid-July 2026, Numinus may pursue an equity raise or other recapitalization at around $0.02 to address negative equity and limited cash.
- Sun31May
Actual outcome: Mixed · $0.02 at outcome
NUMIF reported FQ2 2026 EPS of -$0.0023, exactly meeting analyst estimates. However, the stock drifted down to the $0.02 bear floor by the outcome date, as the results and going-concern update failed to provide the necessary reassurance around revenue stabilization and cost cuts to drive a recovery.
FQ2 2026 earnings on 2026-05-31, with focus on revenue stabilization, cost cuts, and going-concern language at a $0.04 share price.
- Tue21Apr
Actual outcome: Bull · $0.04 at outcome
NUMIF surged after a federal executive order accelerated psychedelic treatment research, aligning with its clinical programs. The move reflects heightened expectations for regulatory support and faster timelines, which directly impact the company's research pipeline and potential market access. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-17: +378.7% from 2026-04-08 (~7.0σ). Target date 2026-04-29 reached; move through 2026-08-17 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-18: +378.7% from 2026-04-08 (~7.0σ). Target date 2026-04-29 reached; move through 2026-08-18 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-20: +378.7% from 2026-04-08 (~7.0σ). Target date 2026-04-29 reached; move through 2026-08-20 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-24: +378.7% from 2026-04-08 (~7.0σ). Target date 2026-04-29 reached; move through 2026-08-24 observed.
NUMIF surged after a federal executive order accelerated psychedelic treatment research, aligning with its clinical programs. The move reflects heightened expectations for regulatory support and faster timelines, which directly impact the company's research pipeline and potential market access. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-17: +378.7% from 2026-04-08 (~7.0σ). Target date 2026-04-29 reached; move through 2026-08-17 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-18: +378.7% from 2026-04-08 (~7.0σ). Target date 2026-04-29 reached; move through 2026-08-18 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-20: +378.7% from 2026-04-08 (~7.0σ). Target date 2026-04-29 reached; move through 2026-08-20 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-24: +378.7% from 2026-04-08 (~7.0σ). Target date 2026-04-29 reached; move through 2026-08-24 observed.
